Drug Approval | March 11, 2025
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The company is the Clinical Research Organisation of Caplin Point Laboratories
The clinical research organisation located in Hyderabad is a USFDA inspected facility
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Subscribe To Our Newsletter & Stay Updated
